Payment overview · 2025
General Payments
$496.91
22 reported records · 9 companies
Healthcare provider profile · identity verified
Barbara Ann Hrach, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SANTA BARBARA, CA · NPI 1164575536
Verified facts
What the public records show
CMS Open Payments records show Barbara Ann Hrach, M.D. received $496.91 in general payments during 2025 across 22 reported records.
Amgen Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic, Prolia.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.66 | 21.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.06 | 14.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.91 | 13.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $66.85 | 13.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $56.66 | 11.4% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.42 | 11.2% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.54 | 5.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.41 | 4.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.40 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.91 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $74.20 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.06 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $66.85 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $66.85 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $66.85 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $56.66 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.42 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $46.17 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $30.46 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $25.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 38 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 171 | 36 |
| Atorvastatin Calcium | Atorvastatin Calcium | 169 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 114 | 27 |
| Celecoxib | Celecoxib | 113 | 28 |
| Losartan Potassium | Losartan Potassium | 113 | 25 |
| Simvastatin | Simvastatin | 112 | 16 |
| Lorazepam | Lorazepam | 99 | 29 |
| Gabapentin | Gabapentin | 95 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 24 |
| Carbamazepine | Carbamazepine | 87 | suppressed |
| Alprazolam | Alprazolam | 85 | 25 |
| Levetiracetam | Levetiracetam | 85 | suppressed |
| Omeprazole | Omeprazole | 84 | 13 |
| Trazodone Hcl | Trazodone Hcl | 73 | 19 |
| Eliquis | Apixaban | 71 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 14 |
| Tramadol Hcl | Tramadol Hcl | 60 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 12 |
| Baclofen | Baclofen | 54 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 54 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 16 |
| Metformin Hcl | Metformin Hcl | 52 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 17 |
| Jardiance | Empagliflozin | 51 | suppressed |
| Spironolactone | Spironolactone | 51 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 11 |
| Diazepam | Diazepam | 48 | suppressed |
| Potassium Chloride | Potassium Chloride | 46 | 11 |
| Clonazepam | Clonazepam | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 45 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 42 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 38 | 38 |
| Furosemide | Furosemide | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Zonisamide | Zonisamide | 36 | suppressed |
| Lisinopril | Lisinopril | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 23 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 33 | 26 |
| Valsartan | Valsartan | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Allopurinol | Allopurinol | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Carvedilol | Carvedilol | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Estradiol | Estradiol | 20 | 12 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Clonidine | Clonidine | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Meloxicam | Meloxicam | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Yuvafem | Estradiol | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.91 · 22 records | Amgen Inc. | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, EVENITY, GARDASIL 9, KRYSTEXXA, Kerendia, M-M-R II, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, Rybelsus, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error